regonext: 2l regorafenib in patients with unresectable hcc who have progressed on atezo-bev
Published 7 months ago • 237 plays • Length 1:15Download video MP4
Download video MP3
Similar videos
-
2:52
refine: a real-world analysis of regorafenib in patients with unresectable hcc
-
2:14
stellar-303: xl092 with atezolizumab compared to regorafenib in patients with mcrc
-
1:49
regorafenib and pembrolizumab in pre-treated hepatocellular carcinoma
-
3:11
regorafenib in advanced hcc
-
4:32
first-line regorafenib 80mg/day with pembrolizumab in advanced hcc
-
2:32
stellar-303: xl092 with atezolizumab or regorafenib in patients with mcrc
-
4:07
80mg regorafenib plus pembrolizumab for 1l hcc
-
1:09
survival benefit confirmed in real-life analysis of second-line regorafenib in hcc
-
1:16
integrate iia: regorafenib in refractory advanced gastro-esophageal cancer
-
3:48
clinical experience with regorafenib in hcc
-
3:56
comparative efficacy of cabozantinib and regorafenib for advanced hepatocellular carcinoma
-
3:10
regorafenib in refractory biliary tract cancer
-
7:46
clinical use of regorafenib in mhcc
-
1:27
dr. sherman on the role of regorafenib in liver cancer
-
1:23
the rationale for combining regorafenib with io to treat patients with refractory mss-crc
-
1:51
managing side effects with regorafenib in hcc
-
7:01
global use of regorafenib in hcc
-
0:49
dr. bendell on remaining questions with regorafenib in hcc
-
2:04
dr. bruix on regorafenib in second-line hcc